Exact Sciences Corporation (NASDAQ:EXAS)‘s stock had its “buy” rating restated by Canaccord Genuity in a research report issued on Thursday, The Fly reports. They presently have a $42.00 price target on the medical research company’s stock, up from their previous price target of $38.00. Canaccord Genuity’s target price would suggest a potential upside of 7.58% from the company’s previous close.

Several other equities research analysts have also commented on the company. Bank of America Corporation restated a “buy” rating on shares of Exact Sciences Corporation in a research report on Wednesday, March 29th. Cowen and Company upped their price objective on Exact Sciences Corporation from $30.00 to $40.00 and gave the stock an “outperform” rating in a research report on Thursday, April 27th. Zacks Investment Research lowered Exact Sciences Corporation from a “hold” rating to a “sell” rating in a research report on Tuesday, April 25th. Vetr upgraded Exact Sciences Corporation from a “buy” rating to a “strong-buy” rating and set a $37.66 price objective on the stock in a research report on Tuesday, May 30th. Finally, Goldman Sachs Group, Inc. (The) set a $33.00 price objective on Exact Sciences Corporation and gave the stock a “neutral” rating in a research report on Monday, May 1st. One investment analyst has rated the stock with a sell rating, five have given a hold rating and twelve have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $35.73.

Exact Sciences Corporation (NASDAQ:EXAS) traded down 0.26% during trading on Thursday, hitting $39.04. 1,710,184 shares of the company were exchanged. Exact Sciences Corporation has a 1-year low of $11.96 and a 1-year high of $39.99. The stock’s market capitalization is $4.34 billion. The firm’s 50 day moving average price is $35.75 and its 200-day moving average price is $26.45.

Exact Sciences Corporation (NASDAQ:EXAS) last released its quarterly earnings data on Thursday, April 27th. The medical research company reported ($0.32) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.41) by $0.09. Exact Sciences Corporation had a negative return on equity of 49.24% and a negative net margin of 116.39%. The business had revenue of $48.36 million for the quarter, compared to analyst estimates of $37.38 million. During the same quarter in the prior year, the firm posted ($0.49) EPS. The business’s quarterly revenue was up 225.9% compared to the same quarter last year. Equities analysts predict that Exact Sciences Corporation will post ($1.33) EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Canaccord Genuity Reiterates “Buy” Rating for Exact Sciences Corporation (NASDAQ:EXAS)” was first posted by American Banking News and is the property of of American Banking News. If you are accessing this story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this story can be read at https://www.americanbankingnews.com/2017/07/20/canaccord-genuity-reiterates-buy-rating-for-exact-sciences-corporation-nasdaqexas.html.

In other news, SVP D Scott Coward sold 1,987 shares of the stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $35.21, for a total transaction of $69,962.27. Following the transaction, the senior vice president now owns 57,603 shares in the company, valued at approximately $2,028,201.63. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 4.00% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Botty Investors LLC purchased a new position in Exact Sciences Corporation during the first quarter valued at approximately $200,000. Eqis Capital Management Inc. purchased a new position in Exact Sciences Corporation during the first quarter valued at approximately $201,000. Teacher Retirement System of Texas purchased a new position in Exact Sciences Corporation during the first quarter valued at approximately $203,000. Ameritas Investment Partners Inc. increased its position in Exact Sciences Corporation by 455.0% in the first quarter. Ameritas Investment Partners Inc. now owns 9,129 shares of the medical research company’s stock valued at $216,000 after buying an additional 7,484 shares in the last quarter. Finally, Lincoln National Corp purchased a new position in Exact Sciences Corporation during the first quarter valued at approximately $221,000. 85.08% of the stock is owned by hedge funds and other institutional investors.

Exact Sciences Corporation Company Profile

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

The Fly

Analyst Recommendations for Exact Sciences Corporation (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.